The influence of NRAS mutations in response to LDAC has been reported previously; for example, Bloomfield and colleagues showed that patients with AML carrying mutant RAS benefit from high-dose cytarabine (HDAC) consolidation more so than patients with wild-type RAS [15], and they also exhibit a lower relapse risk (HR 0.28, p = 0.002) than patients with mutant RAS treated with LDAC. Here, NRAS is linked to acute myeloid leukemia.